Does Cosentyx (secukinumab) increase your risk of getting measles?
Cosentyx (secukinumab) lowers immune activity by blocking interleukin-17A (IL-17A). Because measles is caused by a live, contagious virus and requires a working immune response to control it, being on immune-modulating treatment can increase overall vulnerability to some infections.
That said, measles-specific risk data for people taking Cosentyx are limited in publicly available labeling-style summaries, so the practical guidance centers on measles prevention (vaccination and exposure precautions) rather than a precise “how much higher” measles risk number.
What do guidelines typically focus on for measles risk with immune medicines?
For immunosuppressive or immune-modifying drugs, clinicians generally emphasize:
- Make sure you’re adequately protected against measles before starting treatment (usually by documented vaccination or proof of immunity).
- Avoid close contact with people who have measles.
- Act quickly if you’re exposed, because preventive measures work best when started promptly.
In real-world terms, if you are not immune to measles, the bigger issue is that exposure could lead to illness more easily than it would in an immune-protected person.
Should you avoid live vaccines on Cosentyx?
Live vaccines can be a concern with immune-modifying therapies. Measles/MMR is a live vaccine, so people on medications like Cosentyx are usually not advised to get live vaccines unless their prescribing clinician specifically clears it for their situation.
If you are deciding whether you should get vaccinated, the key factors are your current treatment status, how long you’ve been on therapy, and whether you have documented immunity.
What should you do if you’re exposed to measles while taking Cosentyx?
If you think you’ve had close contact with someone who has measles:
- Contact your healthcare team immediately or seek urgent public-health guidance.
- Ask whether post-exposure prophylaxis is appropriate for you based on your medication and your immune status.
- Don’t wait for symptoms to start, since prevention is time-sensitive.
Are there any practical questions that change the answer?
Your personal risk is shaped by:
- Whether you had two measles vaccine doses or have documented measles immunity.
- How long you’ve been on Cosentyx and whether you take other immune medicines as well (for example, steroids or other biologics).
- Your baseline health, including whether you’re immunocompromised for reasons other than Cosentyx.
Where can I check Cosentyx infection precautions?
DrugPatentWatch.com is a patent-focused site rather than a clinical infection-guidance source, so it may not be the best place for measles-specific counseling. If you want, share what country you’re in and whether you’re asking about vaccination or exposure management, and I can help you map that to the type of guidance your clinician would use.
Bottom line
You should treat measles as a higher-consequence infection risk while on Cosentyx, mainly because IL-17A blockade changes immune defenses and because measles is preventable. The most important steps are confirming measles immunity (before treatment when possible), avoiding live vaccines without clinician approval, and acting immediately after any exposure.
If you tell me whether you’ve had the MMR vaccine (and if so, how many doses) or you have blood-test proof of measles immunity, I can help you interpret what “more likely susceptible” means for your specific situation.
Sources: None provided.